Novartis (NVS) Stock Price, News & Analysis

Company Overview

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies. Novartis has historically included generics and biosimilars through the Sandoz business and previously separated its eye-care business, Alcon, as an independent company; its portfolio and organizational structure have evolved through acquisitions, divestitures and strategic partnerships.

Research and development is a core part of Novartis’s operating model, with sustained investment in early-stage discovery, clinical trials and regulatory submissions. The company leverages a mix of small-molecule drugs, monoclonal antibodies, novel platforms and digital-health initiatives to advance its pipeline and to support commercialization in markets across the Americas, Europe, Asia-Pacific and other regions.

Novartis is publicly traded and reports under the ticker NVS on the New York Stock Exchange as well as on the SIX Swiss Exchange. The company is led by Chief Executive Officer Vas Narasimhan and maintains a global leadership and research footprint intended to accelerate development of new therapies and expand patient access to approved medicines.

Key Stats

• Today's Range: $149.32 to $151.41
• 50-Day Range: $142.99 to $163.03
• 52-Week Range: $111.06 to $170.46
• Volume: 998,975 shs
• Average Volume: 1.42 million shs
• Market Capitalization: $286.96 billion
• P/E Ratio: 21.55
• Dividend Yield: 2.05%
• Price Target: $141.20
• Consensus Rating: Hold

Novartis Stock Analysis - MarketRank™

Novartis scored higher than 58% of companies evaluated by MarketBeat, and ranked 456th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Novartis has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on no strong buy ratings, 7 buy ratings, 7 hold ratings, and 2 sell ratings.

Downside Risk

Novartis has a consensus price target of $141.20, representing about 6.1% downside from its current price of $150.39.

Amount of Analyst Coverage

Novartis has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 11.20%

Earnings Growth

Earnings for Novartis are expected to grow by 11.20% in the coming year, from $8.84 to $9.83 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novartis is 21.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novartis is 21.55, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.78.

Price to Earnings Growth Ratio

Novartis has a PEG Ratio of 2.62. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novartis has a P/B Ratio of 7.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.24% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 2.95, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently decreased by 22.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novartis pays a meaningful dividend of 2.07%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novartis does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novartis is 44.13%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novartis will have a dividend payout ratio of 31.33% next year. This indicates that Novartis will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.20

News Sentiment

Novartis has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Novartis this week, compared to 10 articles on an average week.

Search Interest

4 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 6 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novartis insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.01% of the stock of Novartis is held by insiders.

Percentage Held by Institutions

13.12% of the stock of Novartis is held by institutions.

Company Calendar

• Record date for 3/16 Dividend: 3/11/2026
• Ex-Dividend for 3/16 Dividend: 3/11/2026
• Dividend Payable: 3/16/2026
• Last Earnings: 4/27/2026
• Today: 5/19/2026
• Next Earnings (Estimated): 7/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NVS
• CIK: 1114448
• Web: www.novartis.com
• Phone: (161) 324-1111
• Fax: 41-61-324-7826
• Employees: 75,267
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Novartis: $141.20
• High Price Target: $180.00
• Low Price Target: $112.00
• Potential Upside/Downside: -6.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.31
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.98
• Trailing P/E Ratio: 21.55
• Forward P/E Ratio: 17.01
• P/E Growth: 2.62
• Net Income: $13.98 billion
• Net Margins: 24.87%
• Pretax Margin: 29.01%
• Return on Equity: 38.82%
• Return on Assets: 15.16%

Debt

• Debt-to-Equity Ratio: 0.96
• Current Ratio: 0.85
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $54.53 billion
• Price / Sales: 5.26
• Cash Flow: $10.83 per share
• Price / Cash Flow: 13.89
• Book Value: $20.40 per share
• Price / Book: 7.37

Miscellaneous

• Outstanding Shares: 1,908,150,000
• Free Float: 1,907,961,000
• Market Cap: $286.96 billion
• Optionable: Optionable
• Beta: 0.46